Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib, Avelumab and Palbociclib in Metastatic ccRCC
NCT05176288Phase 2Withdrawn
- Start
- May 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in clear cell renal cell carcinoma (ccRCC). Primary endpoint: Best Overall Response Rate up to 100 months. Planned start May 2024; status: withdrawn.
02
Drugs
palbociclib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05176288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176288.